SCHEMBL7078286

SCHEMBL7078286

O=C(CC(=O)c1ccc(Cc2ccccc2)s1)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 3/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GRM4 Q14833 1/20 0.44
CTNNB1 P35222 3/20 0.43
LMNA P02545 2/20 0.41
NAPRT Q6XQN6 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
TLR7 Q9NYK1 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
NPC1 O15118 2/20 0.40
TP53 P04637 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081256 0.87 LMNA (0.47) L3MBTL1ALDH1A1THRBSMN1; SMN2MAPT
SCHEMBL7078399 0.84 RAB9A (0.40) ALDH1A1SMN1; SMN2MAPTKDM4ELMNA
SCHEMBL14624675 0.78 ALDH1A1 (0.67) L3MBTL1ALDH1A1THRBSMN1; SMN2MAPT
SCHEMBL7830529 0.77 ERCC5 (0.59) L3MBTL1MAPTPOLBKMT2A
SCHEMBL253276 0.76 CES2 (0.64) L3MBTL1ALDH1A1SMN1; SMN2GRM4CTNNB1
SCHEMBL29355245 0.76 CES2 (0.64) L3MBTL1ALDH1A1SMN1; SMN2GRM4CTNNB1
SCHEMBL4675103 0.73 ALOX5 (0.47) ALDH1A1MAPTKDM4EPOLBTP53
SCHEMBL4625845 0.72 KMT2A (0.63) L3MBTL1ALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL14624343 0.72 SMN1; SMN2 (0.56) ALDH1A1THRBSMN1; SMN2MAPTHTT
SCHEMBL9493294 0.71 LMNA (0.61) L3MBTL1ALDH1A1SMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US claimed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP claimed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP claimed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 L3MBTL1 1944/4885ALDH1A1 145/4885THRB 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.